{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:18:35Z","timestamp":1779164315949,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003010","name":"Ege University","doi-asserted-by":"publisher","award":["32019"],"award-info":[{"award-number":["32019"]}],"id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.gene.2025.149965","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:24:53Z","timestamp":1765931093000},"page":"149965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In vitro expression and seroreactivity of Toxoplasma gondii GRA1 protein encoded by unmodified and nucleoside-modified mRNA constructs"],"prefix":"10.1016","volume":"982","author":[{"given":"Mehmet Nadir","family":"\u015eahinci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mert","family":"D\u00f6\u015fkaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet","family":"Karakavuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seren","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gizem","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu\u011f\u00e7e Gizem","family":"Per\u00e7in","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedef","family":"Erkunt Alak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zlem","family":"G\u00fcnay-Esiyok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayt\u00fcl","family":"G\u00fcl Mete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysu","family":"De\u011firmenci D\u00f6\u015fkaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe G\u00fclten","family":"Kantarc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan Y\u00fcksel","family":"G\u00fcr\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fcseyin","family":"Can","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2025.149965_b0005","first-page":"111","article-title":"Messenger RNA-based vaccines against infectious diseases","volume":"440","author":"Alameh","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.gene.2025.149965_b0010","doi-asserted-by":"crossref","unstructured":"Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... COVE Study Group. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. The New England Journal of Medicine, 384(5), 403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","DOI":"10.1056\/NEJMoa2035389"},{"issue":"1","key":"10.1016\/j.gene.2025.149965_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A trans-amplifying RNA vaccine strategy for induction of potent protective immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"issue":"8","key":"10.1016\/j.gene.2025.149965_b0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0169-4758(94)90078-7","article-title":"Dense-granule organelles of Toxoplasma gondii: their role in the host-parasite relationship","volume":"10","author":"Cesbron-Delauw","year":"1994","journal-title":"Parasitology Today (personal Ed.)"},{"issue":"19","key":"10.1016\/j.gene.2025.149965_b0025","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.86.19.7537","article-title":"Molecular characterization of a 23-kilodalton major antigen secreted by Toxoplasma gondii","volume":"86","author":"Cesbron-Delauw","year":"1989","journal-title":"PNAS"},{"issue":"29","key":"10.1016\/j.gene.2025.149965_b0030","doi-asserted-by":"crossref","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"PNAS"},{"key":"10.1016\/j.gene.2025.149965_b0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s42003-020-01167-x","article-title":"Maximizing transcription of nucleic acids with efficient T7 promoters","volume":"3","author":"Conrad","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.gene.2025.149965_b0040","unstructured":"Coronavirus Vaccine, Patent number: EP 3 901 260 A1, publication date: 27.10.2021."},{"issue":"9","key":"10.1016\/j.gene.2025.149965_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108329","article-title":"Diagnostic value of a Rec-ELISA using Toxoplasma gondii recombinant SporoSAG, BAG1, and GRA1 proteins in murine models infected orally with tissue cysts and oocysts","volume":"9","author":"D\u00f6\u015fkaya","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.gene.2025.149965_b0050","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.vaccine.2006.10.060","article-title":"GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine","volume":"25","author":"D\u00f6\u015fkaya","year":"2007","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.gene.2025.149965_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetpar.2009.02.026","article-title":"Toxoplasmosis in sheep\u2014the last 20 years","volume":"163","author":"Dubey","year":"2009","journal-title":"Vet. Parasitol."},{"issue":"4","key":"10.1016\/j.gene.2025.149965_b0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pt.2010.01.009","article-title":"Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention","volume":"26","author":"Elmore","year":"2010","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.gene.2025.149965_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2024.149073","article-title":"An optimized ROP6 mRNA constructs successfully expressed immunogenic Toxoplasma gondii ROP6 protein in cell culture","volume":"935","author":"Erkunt Alak","year":"2025","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.gene.2025.149965_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090203","article-title":"Toxoplasmosis\u2014a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries","volume":"9","author":"Flegr","year":"2014","journal-title":"PLoS One"},{"issue":"7893","key":"10.1016\/j.gene.2025.149965_b0075","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-04231-6","article-title":"Optimization of non-coding regions for a nonmodified mRNA COVID-19 vaccine","volume":"601","author":"Gebre","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.gene.2025.149965_b0080","article-title":"Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2","volume":"142","author":"Granados-Riveron","year":"2021","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"24","key":"10.1016\/j.gene.2025.149965_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.06.032","article-title":"A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis","volume":"42","author":"G\u00fcl","year":"2024","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.gene.2025.149965_b0090","first-page":"253","article-title":"An overview of DNA vaccines development studies against Toxoplasma gondii","volume":"46","author":"G\u00fcl","year":"2022","journal-title":"T\u00fcrkiye Parazitoloji Dergisi"},{"issue":"2","key":"10.1016\/j.gene.2025.149965_b0095","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1002\/cpz1.39","article-title":"Cap 1 messenger RNA synthesis with co-transcriptional CleanCap\u00ae analog by in vitro transcription","volume":"1","author":"Henderson","year":"2021","journal-title":"Current Protocols"},{"issue":"10","key":"10.1016\/j.gene.2025.149965_b0100","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1469-0691.2002.00485.x","article-title":"Toxoplasma gondii: transmission, diagnosis and prevention","volume":"8","author":"Hill","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"issue":"13","key":"10.1016\/j.gene.2025.149965_b0105","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.gene.2025.149965_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.105016","article-title":"GRA8 DNA vaccine formulations protect against chronic toxoplasmosis","volume":"158","author":"Karakavuk","year":"2021","journal-title":"Microb. Pathog."},{"issue":"4","key":"10.1016\/j.gene.2025.149965_b0115","first-page":"342","article-title":"Biotechnological based recombinant protein vaccines developed against toxoplasmosis","volume":"46","author":"Karakavuk","year":"2022","journal-title":"T\u00fcrkiye Parazitoloji Dergisi"},{"issue":"2","key":"10.1016\/j.gene.2025.149965_b0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.gene.2025.149965_b0125","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"issue":"1","key":"10.1016\/j.gene.2025.149965_b0130","first-page":"1","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol. CellToxicol."},{"issue":"3","key":"10.1016\/j.gene.2025.149965_b0135","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.gene.2025.149965_b0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","article-title":"Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine","volume":"156","author":"Kwon","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.gene.2025.149965_b0145","article-title":"A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice","volume":"14","author":"Li","year":"2023","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.gene.2025.149965_b0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.gene.2025.149965_b0155","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/pharmaceutics14051101","article-title":"Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and its Variants","volume":"14","author":"Liu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.gene.2025.149965_b0160","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fmicb.2017.00605","article-title":"Induction of protective immunity against Toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP)","volume":"8","author":"Luo","year":"2017","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.gene.2025.149965_b0165","doi-asserted-by":"crossref","first-page":"19845","DOI":"10.1038\/s41598-024-70792-x","article-title":"Optimization of the 5' untranslated region of mRNA vaccines","volume":"14","author":"Ma","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.gene.2025.149965_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1272221","article-title":"Dense granule protein 3 of Toxoplasma gondii plays a crucial role in the capability of the tissue cysts of the parasite to persist in the presence of anti-cyst CD8+ T cells during the chronic stage of infection","volume":"14","author":"Mani","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gene.2025.149965_b0175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.omtm.2022.03.013","article-title":"Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models","volume":"25","author":"Palladino","year":"2022","journal-title":"Molecular Therapy. Methods & Clinical Development"},{"issue":"1","key":"10.1016\/j.gene.2025.149965_b0180","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"issue":"27","key":"10.1016\/j.gene.2025.149965_b0185","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.gene.2025.149965_b0190","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/bit.28299","article-title":"Increasing yield of in vitro transcription reaction with at-line high pressure liquid chromatography monitoring","volume":"120","author":"Pregeljc","year":"2023","journal-title":"Biotechnol. Bioeng."},{"issue":"12\u201313","key":"10.1016\/j.gene.2025.149965_b0195","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: from animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int. J.Parasitol."},{"issue":"2","key":"10.1016\/j.gene.2025.149965_b0200","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4161\/hv.22474","article-title":"Development of Toxoplasma gondii vaccine: a global challenge","volume":"9","author":"Verma","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.gene.2025.149965_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107534","article-title":"The challenge and prospect of mRNA therapeutics landscape","volume":"40","author":"Weng","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.gene.2025.149965_b0210","doi-asserted-by":"crossref","unstructured":"Wilson, E., Goswami, J., Baqui, A. H., Doreski, P. A., Perez-Marc, G., Zaman, K., Monroy, J., Duncan, C. J. A., Ujiie, M., R\u00e4met, M., P\u00e9rez-Breva, L., Falsey, A. R., Walsh, E. E., Dhar, R., Wilson, L., Du, J., Ghaswalla, P., Kapoor, A., Lan, L., Mehta, S., \u2026 ConquerRSV Study Group (2023). Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. The New England journal of medicine, 389(24), 2233\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2307079.","DOI":"10.1056\/NEJMoa2307079"},{"key":"10.1016\/j.gene.2025.149965_b0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00563-0","article-title":"Toxoplasmosis vaccines: what we have and where to go?","volume":"7","author":"Zhang","year":"2022","journal-title":"npj Vaccines"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925007553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925007553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:39:49Z","timestamp":1768937989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111925007553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"alternative-id":["S0378111925007553"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2025.149965","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro expression and seroreactivity of Toxoplasma gondii GRA1 protein encoded by unmodified and nucleoside-modified mRNA constructs","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2025.149965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149965"}}